Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 10Etoposide 6Doxorubicin 6Cytarabine 6Prednisone 5Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Methotrexate 4gamma-Globulins 3Rituximab 3Radiotherapy 3Filgrastim 3Ciprofloxacin 3pegaspargase 2nelarabine 2etoposide phosphate 2calaspargase pegol 2Triptorelin Pamoate 2Thioguanine 2Prednisolone 2Methylprednisolone 2Mercaptopurine 2Melphalan 2Magnetic Resonance Spectroscopy 2Immunoglobulins, Intravenous 2Dexamethasone 2Daunorubicin 2Cyclosporine 2Calcium Dobesilate 2Bortezomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma × epratuzumab × Clear all
NCT00003338 2021-08-16

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Gilead Sciences

Phase 2/3 Unknown
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡